Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

According to the latest tokenized commodities market data, Tether Gold and PAX Gold have driven the value of total assets ...

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancerPhase 3 PANOVA-3 trial showed a ...

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...

At a time when almost every major cryptocurrency is in the red, these two cryptos are soaring higher.

NovoCure Ltd NVCR shares are trending on Thursday. Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

The FDA approved Optune Pax for locally advanced pancreatic cancer. ・The Panova-3 trial showed Optune Pax, used alongside ...

With Season 2 fast approaching, EA reveals new details on what Battlefield 6 players can expect to see in regards to ...

The FDA has cleared a wearable device for adults with locally advanced pancreatic cancer that delivers low-intensity electric ...

Battlefield 6 Season 2 will start on February 17 at 4 AM PT. Per the developers, Season 2 will be released in three separate phases: Extreme Measures, Nightfall, and Hunter/Prey. Extreme Measures ...